Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic hepatitis C Age: Adult Condition: Ribavirin with peginterferon alfa 2b |
Dose: Oral – 800 mg/day (400 mg morning and 400 mg evening) Frequency: daily Note: Administered with peginterferon 1.5 mcg/kg/week subcutaneous injection. |
|
Indication: Chronic hepatitis C Age: Adult Condition: Ribavirin with peginterferon alfa 2b |
Dose: Oral – 1000 mg/day (400 mg morning and 600 mg evening) Frequency: daily Note: Administered with peginterferon 1.5 mcg/kg/week subcutaneous injection. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic hepatitis C Age: greater than 3 years |
Dose: Oral – 15 mg/kg/day Note: plus peginterferon alfa-2b 60 mcg/m2 subcutaneously every week; Length of treatment determined by genotype; genotypes 2 or 3 administer for 24 weeks, for genotype 1 is 48 weeks |
|
Indication: Chronic hepatitis C Age: greater than 3 years |
Dose: Oral – 400 mg Frequency: every 12 hours Note: by mouth (oral); plus peginterferon alfa-2b 60 mcg/m2 subcutaneously every week; Length of treatment determined by genotype; genotypes 2 or 3 administer for 24 weeks, for genotype 1 is 48 weeks |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Dosage – Not specified Note: Avoid usage |
Administration
- Can be taken with or without food
- Take consistently with respect to meals
Side Effect
- Fatigue (60-70%)
- Headache (63-66%)
- Hemolysis (61-64%)
- Myalgia (61-64%)
- Nausea (38-47%)
- Rigors (40-43%)
- Fever (32-41%)
- Insomnia (26-39%)
- Decreased Hgb (25-36%)
- Depression (23-36%)
- Hyperbilirubinemia (24-34%)
- Arthralgia (29-33%)
- Alopecia (27-32%)
- Irritability (23-32%)
- Musculoskeletal pain (20-28%)
- Rash (20-28%)
- Anorexia (21-27%)
- Dizziness (17-26%)
- Pruritus (13-21%)
- Flu-like syndrome (13-18%)
- Dyspnea (17-19%)
- Nasal congestion (13-18%)
- Dyspepsia (14-16%)
- Impaired concentration (10-14%)
- Thrombocytopenia (6-14%)
- Sinusitis (9-12%)
- Vomiting (9-12%)
- Emotional lability (7-12%)
- Decreased WBC
- ANC Less than 500 /cu
- mm (5-11%)
- Hemolytic anemia (~10%)
- Weakness (9-10%)
- Chest pain (5-9%)
- Taste perversion (6-8%)
- Nervousness (~5%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Interferon alfa
|
May worsen neutropenia
|
|
Nucleoside Reverse Transcriptase Inhibitors (Zidovudine, Lamivudine, Stavudine, Didanosine)
|
May increase risk of adverse effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Cardiac Disease
|
Risk of heart complications
|
|
Hemoglobinopathies
|
Can worsen anemia
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep out of the reach of children. Keep in a cool & dry place. Protect from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.